Day: March 26, 2025

ROCK HILL, S.C., March 26, 2025 (GLOBE NEWSWIRE) — 3D Systems Corporation (NYSE:DDD) announced today its financial results for the fourth quarter and full year ended December 31, 2024.Full-year 2024 revenue of $440 million, above lower end of guidance range, inclusive of a $9 million revenue reduction in Q4 driven by a change in accounting estimates for Regenerative Medicine program milestone recognition. This change in estimate is related to the now anticipated use of pre-clinical human decedent testing, successfully demonstrated by our partner, United Therapeutics, which led to refinement of the milestone technical criteria. Continued reduction in operating expenses in Q4 reflecting the company’s focus on cost savings and efficiency improvements. Announcement of a new cost reduction initiative expected to deliver over $50 million...

Exceeds first quarter revenue and profit guidance Reiterates full year guidance and remains on track to generate approximately $625 million to $650 million of adjusted free cash flow for the year Expects to return more than $240 million to shareholders in fiscal 2025 through share repurchases and dividends Ongoing momentum and demand for iX Hello™ AI productsNEWARK, Calif., March 26, 2025 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, today announced financial results for the fiscal first quarter ended February 28, 2025.  Three Months Ended      February 28, 2025   February 29, 2024   ChangeRevenue ($M) $ 2,372.2     $ 2,402.7     (1.3)%Operating income ($M) $ 168.9     $ 148.4     13.8 %Non-GAAP operating income ($M) (1) $ 321.5     $ 319.1     0.8 %Operating...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our next generation targeted radiopharmaceutical technology platform Enrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 30 patients enrolled through end of February 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumors Achieved first-in-human combination dosing of a PD-1 inhibitor with one of our potential new medicines, with recent dosing of VMT01 in combination with nivolumab IND cleared for PSV359, which targets FAP-α, associated with multiple highly prevalent solid tumors, with patients in need of additional treatment options. First patient dosing expected in mid-2025 Continued progress...

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced financial results for the year ended December 31, 2024, and highlighted recent corporate accomplishments. “Zentalis...

Fourth quarter results compared to prior year:Orders grew 9%, driven by 12% broad-based growth in the Americas Gross margin improved 70 basis pointsFiscal 2025 results:Orders grew 4%, driven by 6% growth in the Americas compared to prior year Gross margin improved 110 basis points compared to prior year, including benefits from cost reduction initiatives Operating income margin reached 5.0%, an improvement of 130 basis points compared to the prior year Adjusted earnings per share exceeded company targets Returned $84 million to shareholders Total liquidity strengthened by $73 millionCompany provides financial targets for fiscal 2026 of mid-single digit organic revenue growth and modest adjusted operating margin expansionGRAND RAPIDS, Mich., March 26, 2025 (GLOBE NEWSWIRE) — Steelcase Inc. (NYSE: SCS) today reported...

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024 Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower cost Growth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1 Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applications Continued advancements in animal and human health Cash and investment-grade securities of $9.3 million as of December 31, 2024 Financial results and business update conference call scheduled for 5:00 pm ET todayJUPITER, Fla., March 26, 2025 (GLOBE NEWSWIRE) —...

Full Year Revenues up in each of ACH & Complementary Services, Card and Output Solutions Business Units Record Full Year 2024 Dollar Processing Volume of $7.1 Billion, a 33% Increase Compared to Fiscal 2023; Transactions Processed also up a Strong 26% Year-over-Year Cash Position Increases to Record High of $8.1 Million SAN ANTONIO, March 26, 2025 (GLOBE NEWSWIRE) — Usio, Inc: (Nasdaq: USIO), a leading FinTech company that operates a full stack of integrated, cloud-based electronic payment and embedded financial solutions, today announced financial results for the fourth quarter and year ended December 31, 2024. Louis Hoch, Chairman and Chief Executive Officer of Usio, said, “We are delivering on our commitments as profitability improved, cash flow was strong, and revenue grew in each of our ACH & Complementary Services,...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestones Cash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 26, 2025 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate...

CULVER CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) — Snail, Inc. (NASDAQ: SNAL) (“Snail” or “the Company”), a leading, global independent developer and publisher of interactive digital entertainment, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter & Full Year 2024 HighlightsARK: Survival Ascended. On October 25, 2023, the Company launched its flagship remake of the ARK franchise leveraging Unreal Engine 5’s stunning graphics and introduced a game-altering cross-platform modding system, ushering in a new era of creativity.ARK: Survival Ascended was ranked the top #1 selling game on Steam on launch day.   Since its launch, ARK: Survival Ascended sold 3.4 million units and has an average of 94,000 daily active users (“DAUs”) with a peak of 308,000 DAUs.ARK:...